10 Results for "

Y641F

" in MedChemExpress (MCE) Product Catalog:
Products (10)

10 Results for "Y641F" in MCE Product Catalog:

2
2 Cited Publications
Cat. No.: HY-15573
CAS No.: 1418308-27-6
Purity:  99.78%
Synonyms: KB-145943
Research Areas:  

Cancer

EI1 (KB-145943) is a potent and selective EZH2 inhibitor with IC50 of 15 nM and 13 nM for EZH2 (WT) and EZH2 (Y641F), respectively.
loading...
    loading...
Cat. No.: HY-116804
CAS No.: 1826865-46-6
Purity:  99.19%
Research Areas:  

Cancer

ZLD1039 is a potent, highly selective, and orally bioavailable EZH2 inhibitor. ZLD1039 shows potent and concentration-dependent inhibition of PRC2 enzymatic activity against EZH2 wild-type as well as Y641F, and A677G mutant enzymes with IC50 values of 5.6, 15, and 4.0 nM, respectively. ZLD1039 inhibits breast tumor growth and metastasis .
loading...
    loading...
Cat. No.: HY-144881
CAS No.: 2202678-05-3
Research Areas:  

Inflammation/Immunology Cancer

(S)-HH2853 (compound 200), a PYRIDINO five membered aromatic ring compound, is a potent EZH1/2 dual inhibitor with an IC50 of <100 nM for EZH2_Y641F. (S)-HH2853 has the potential to be used in the research of anti-tumor or autoimmune diseases .
loading...
    loading...
Cat. No.: HY-144882
CAS No.: 2202678-06-4
Research Areas:  

Inflammation/Immunology Cancer

(R)-HH2853 is a mutant EZH2 inhibitor with an IC50 of <100 nM for EZH2-Y641F. (R)-HH2853 can be used for cancer and autoimmune diseases (WO2018045971A1; compound 201) .
loading...
    loading...
Cat. No.: HY-156292
CAS No.: 3018914-66-1
Research Areas:  

Cancer

IHMT-EZH2-426 (compound 38) is an effective covalent EZH2 degrader, with IC50 values of 1.3 nM, 1.2 nM, and 1.7-3.5 nM for EZH2 wild type, EZH2-A687V, and EZH2-Y641F/Y641N/Y641S, respectively. IHMT-EZH2-426 reduces H3K27me3 and EZH2 levels and shows effective anti-proliferative effects in B-cell lymphoma and TNBC cell lines.
loading...
    loading...
Cat. No.: HY-149463
CAS No.: 2238820-26-1
Research Areas:  

Cancer

EZH2-IN-16 (Compound 24) is an inhibitor for histone methyltransferase (EZH2). EZH2-IN-16 inhibits EZH2 and EZH2 Y641F, with IC50 of 37.6 and 79.1 nM. EZH2-IN-16 inhibits proliferation of WSU-DLCL2, with GI50 of 0.2 μM .
loading...
    loading...
Cat. No.: HY-154854
CAS No.: 2691174-27-1
Research Areas:  

Cancer

BBDDL2059 is a selective covalent inhibitor of histone methyltransferase EZH2 with an IC50 of 1.5 nM for EZH2-Y641F. BBDDL2059 inhibits lymphoma cell growth at nanomolar concentrations and can be used for anticancer research .
loading...
    loading...
Cat. No.: HY-176135
Research Areas:  

Cancer

BBDDL2204 (compound 13) is a potent and selective EZH2 covalent inhibitor. BBDDL2204 inhibits EZH2 Y641F with an IC50 of 2.5 nM .
loading...
    loading...
Cat. No.: HY-169958
CAS No.: 2766231-05-2
Research Areas:  

Cancer

EZH2-IN-22 (example 92) is a potent EZH2 inhibitor with IC50 values of <0.00051, <0.00051, 0.00052 µM for EZH2 (Y641N), EZH2 (Y641F), EZH2 (wt), respectively. EZH2-IN-22 shows antiproliferation activity .
loading...
    loading...
Cat. No.: HY-143616
CAS No.: 2659225-28-0
Research Areas:  

Cancer

EZH2-IN-7 is a potent inhibitor of EZH2. EZH2 overexpression or mutations in the SET region (Y641F, Y641N, A687V, A677G point mutations) all lead to abnormal elevation of H3K27me3 and promote the growth and development of many types of tumors, such as breast cancer, prostate cancer, leukemia, etc. EZH2-IN-7 has the potential for the research of cancer diseases (extracted from patent WO2021129629A1, compound 259) .
loading...
    loading...